Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 3-year average of 26.23%, near the low end of its 3-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
26.23%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Tvardi Therapeutics, Inc.
Market Cap
$10.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
26.23%
5Y Avg
N/A
Market Cap
$10.06M
Gross Margin
-16431.82%
TTM Avg
-8215.91%
3Y Avg
-4057.95%
5Y Avg
-2671.97%
Market Cap
$10.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$9.83M
Gross Margin
67.30%
TTM Avg
49.28%
3Y Avg
20.15%
5Y Avg
20.34%
Market Cap
$10.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$9.71M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $10.13M | 0.00% | 0.00% | 26.23% | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | -16431.82% | -8215.91% | -4057.95% | -2671.97% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lifeward Ltd. (LFWD)vs › | $10.21M | 35.95% | 35.13% | 34.24% | 39.24% |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | 0.00% | 0.00% | 10.16% | 1.65% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | 67.30% | 49.28% | 20.15% | 20.34% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| MetaVia Inc. (MTVA)vs › | $9.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pluri Inc. (PLUR)vs › | $10.68M | 44.59% | 46.77% | 72.29% | -10.14% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 70.96% |
| 2023-12-31 | 77.03% |
| 2023-09-30 | 66.77% |
